A detailed history of Marks Group Wealth Management, Inc transactions in Argenx Se stock. As of the latest transaction made, Marks Group Wealth Management, Inc holds 1,178 shares of ARGX stock, worth $734,859. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,178
Previous 1,196 1.51%
Holding current value
$734,859
Previous $514,000 24.12%
% of portfolio
0.06%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$434.22 - $551.9 $7,815 - $9,934
-18 Reduced 1.51%
1,178 $638,000
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $3,560 - $4,515
10 Added 0.84%
1,196 $514,000
Q1 2024

Apr 29, 2024

BUY
$356.95 - $413.29 $54,256 - $62,820
152 Added 14.7%
1,186 $466,000
Q4 2023

Feb 01, 2024

BUY
$338.91 - $506.01 $104,723 - $156,357
309 Added 42.62%
1,034 $393,000
Q3 2023

Oct 30, 2023

BUY
$369.35 - $548.43 $267,778 - $397,611
725 New
725 $356,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Marks Group Wealth Management, Inc Portfolio

Follow Marks Group Wealth Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marks Group Wealth Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Marks Group Wealth Management, Inc with notifications on news.